Genetic Privacy, GINA, and Insurance: What to Know Before You Test for APOE4

There is a federal law that stops your health insurer and your employer from ever using an APOE4 result against you. It is called GINA, and it is real protection. The catch is the part nobody puts in the headline: GINA does nothing about life insurance, long-term-care insurance, or disability insurance. Those three are exactly the products an APOE4 carrier might want most, and in the United States they can legally underwrite using a genetic result. That single gap, not the gene itself, is the thing most carriers should think through before they test through a doctor.

This is the practical and legal side of testing, so before the medical stuff: this is general information, not legal advice, and the rules change and vary by state and country. Use it to ask better questions, not to make a final call alone.

What GINA actually protects

GINA stands for the Genetic Information Nondiscrimination Act, passed in 2008. It does two clean things, and both matter.

First, health insurers cannot use your genetic information. Under GINA they may not use a genetic result, including an APOE4 status, to decide whether you are eligible, what your coverage looks like, how they underwrite you, or what your premium is. This protection covers private health insurance, Medicare, Medicaid, Federal Employees Health Benefits, and Veterans Health Administration coverage.

Second, employers cannot use it either. GINA bars most employers from using genetic information in hiring, firing, pay, promotions, or job assignments, and it limits their ability to even request it.

So the two scenarios people fear most, getting dropped by your health plan or passed over at work because of a gene, are the two scenarios the law was built to prevent.

The gap that actually matters

Here is the language carriers need to know cold. GINA’s protections do not cover long-term-care insurance, life insurance, or disability insurance. For those three, there is no federal law stopping the insurer from using your genetic data when they evaluate your application. They can charge you a higher rate, or decline you outright, based on a known result.

That asymmetry is the whole game. Your health coverage is shielded. The coverage that pays out if you develop a long, expensive neurodegenerative illness, which is precisely the risk APOE4 raises, is not.

GINA also has a few edges worth knowing:

• It does not apply to employers with fewer than 15 employees.
• The U.S. military is allowed to use genetic information in its own employment decisions, an explicit carve-out.
• It governs genetic discrimination. It is not a general medical-privacy law, and it does not erase a result once it exists in a record.

Why a relative gene becomes an absolute decision

Think of GINA as a fence around two of your fields and not the other three. The fence is solid. The problem is that life, LTC, and disability insurance sit on the unfenced side, and an insurer over there is allowed to look at your APOE4 status and price you accordingly.

Now connect it to where the result lives, because that is the other half of the decision.

A clinician-ordered APOE4 test generally lands in your medical record. Life, LTC, and disability applications routinely ask you to disclose your health history and often let the insurer review records. So a doctor-ordered result can surface there.

A direct-to-consumer result, the kind you get from a service like 23andMe, is not automatically in your medical record. But this is not a loophole. Insurance applications can still ask whether you have ever had genetic testing, and you have to answer honestly. Lying on an application can void the policy when you need it most, which defeats the entire purpose of buying it.

The takeaway is not “go around the system.” It is that the type of test changes your record footprint, and the timing of when you apply for coverage is something you control.

The facts in one place

Coverage or actor	Can it use your APOE4 result?	Notes
Health insurance	No	Blocked by GINA (also Medicare, Medicaid, FEHB, VHA)
Employer (15+ employees)	No	Blocked by GINA for hiring, pay, promotion, firing
Employer (under 15)	Not covered by GINA	Outside GINA’s reach
U.S. military	Yes	Explicit carve-out for its employment decisions
Life insurance	Yes	Not covered by GINA
Long-term-care insurance	Yes	Not covered by GINA
Disability insurance	Yes	Not covered by GINA

Where state law and other countries change the picture

A minority of states add protections on top of GINA, but most do not, so you cannot assume coverage exists where you live. Two real examples show the range. California’s CalGINA (2011) extends GINA-style protection into more areas of state life, such as housing, mortgage lending, and education. Florida passed a 2020 law that bars life insurers and long-term-care insurers from canceling, limiting, denying, or repricing coverage based on genetic information, though notably it does not name disability income insurance. The lesson is to check your own state rather than generalize from either one.

Outside the United States, the framework is different again. GINA is U.S. law and does not travel. The United Kingdom, for instance, runs a voluntary insurer agreement under which companies generally do not ask for or use predictive genetic test results for most policies up to set limits. If you are not in the U.S., your own country’s rules are the ones that govern you.

What to actually do before you test

This is where the legal abstraction becomes a checklist.

• Decide about life, LTC, and disability coverage first. A common genetic-counselor tip is to secure any of these policies you think you will want before you test clinically, while you can still answer “no” honestly to questions about genetic results. If coverage matters to you, sort it out before, not after.
• Know your testing route and its record footprint. Understand the difference between a clinical test, a research test, and a direct-to-consumer test: the first generally enters your medical record, the third does not, and that distinction is exactly what insurers can probe.
• Be precise about the DTC path. A 23andMe-style result keeps the data off your medical record, but it does not let you deny having tested. Honesty on the application still applies.
• Loop in family before they test too. Your decision touches relatives, since a result hints at theirs. The trade-offs in should relatives get tested include this same insurance gap.
• Talk to a genetic counselor for a real decision. For anything with money or coverage on the line, get professional advice that fits your state and situation rather than a forum’s.

Common questions

Can my health insurer raise my rates if I test positive for APOE4? No. GINA prohibits health insurers from using genetic information against you in eligibility, coverage, underwriting, or premiums. That protection is solid.

So why do people say to buy life insurance before testing? Because life, long-term-care, and disability insurance are the three products GINA leaves uncovered. Those insurers can legally use a known genetic result to raise your rate or decline you, so locking in coverage before you have a result on the record is a way to keep your options open.

Does a 23andMe test stay off my insurance application? It stays off your medical record, but applications can ask whether you have ever had genetic testing, and you must answer truthfully. A direct-to-consumer test changes your record footprint, not your duty to disclose.

Does GINA protect me in other countries? No. GINA is U.S. law. Other countries handle this differently, such as the U.K.’s voluntary insurer moratorium, so check the rules where you live.

The bottom line: GINA shields your health insurance and your job, but not life, long-term-care, or disability coverage, so sequence those decisions before a clinical test. This is general education, not legal or medical advice, and laws change and vary by state and country, so get professional advice for any real decision.

Sources

• National Human Genome Research Institute. Genetic Discrimination. genome.gov.
• U.S. Equal Employment Opportunity Commission. The Genetic Information Nondiscrimination Act of 2008.
• Prince AER, Berkman BE. Reconceptualizing harms and benefits in the genomic age. PMC, 2018. PMC6354179.
• 110th Congress. H.R. 493, Genetic Information Nondiscrimination Act of 2008. congress.gov.
• Florida Legislature. HB 1189 (2020). flsenate.gov.